論文 - 海北 幸一
-
Aberrant Expression of Cardiac Troponin-T in Lung Cancer Tissues in Association With Pathological Severity. 査読あり
Tsuruda T, Sato Y, Tomita M, Tanaka H, Hatakeyama K, Otsu M, Kawano A, Nagatomo K, Yoshikawa N, Ikeda R, Asada Y, Kaikita K
Frontiers in cardiovascular medicine 9 833649 2022年4月
-
Kurogi K, Ishii M, Ikebe S, Kaichi R, Mori T, Komaki S, Yamamoto N, Yamanaga K, Arima Y, Yamamoto E, Kaikita K, Matsushita K, Tsujita K
Cardiovascular intervention and therapeutics 37 ( 2 ) 312 - 323 2022年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Cardiovascular Intervention and Therapeutics
Optical coherence tomography (OCT) has a higher resolution than intravascular ultrasound (IVUS) and enables a more precise evaluation of calcium severity. We investigated the impact of the imaging method (OCT versus IVUS) on stent expansion during intravascular imaging-guided percutaneous coronary intervention (PCI) in calcified lesions. In this single-center, retrospective, observational study, 145 lesions with moderate to severe calcification were divided into four groups: 40 IVUS-guided rotational atherectomy (RA), 38 IVUS-guided non-RA, 35 OCT-guided RA, and 32 OCT-guided non-RA. Lesions without pre-procedural intravascular imaging were excluded. OCT-guided RA was associated with greater stent expansion at the target calcium compared with IVUS-guided RA (median 88.0%, interquartile range [78.0–96.0] vs. 76.5% [71.0–84.3], P = 0.008). Furthermore, stent expansion in OCT-guided non-RA was similar to OCT-guided RA. OCT-guided RA used a larger burr compared to IVUS-guided RA (1.75 mm [1.50–2.0] vs. 1.50 mm [1.50–1.75], P = 0.004). In OCT-guided RA, the median minimum calcium thickness was significantly reduced from 800 (640–980) µm to 550 (350–680) µm (P < 0.001). There was no significant difference in the incidence of ischemia driven target lesion revascularization between the four groups (P = 0.37). By determining the indication and endpoint of lesion modification by RA based on the thickness of calcium, OCT-guided PCI was associated with significantly greater stent expansion compared with IVUS-guided PCI.
-
Myocardial Tissue Characterization by Combining Extracellular Volume Fraction and T2 Mapping. 査読あり
Kidoh M, Oda S, Nakaura T, Nagayama Y, Funama Y, Takashio S, Kaikita K, Tsujita K, Hirai T
JACC. Cardiovascular imaging 15 ( 4 ) 700 - 704 2022年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：JACC: Cardiovascular Imaging
-
Stratifying Bleeding Risk and Beyond - Predicting Where Bleeding Will Occur. 査読あり
Moribayashi K, Matsuura Y, Kaikita K
Circulation journal : official journal of the Japanese Circulation Society 86 784 - 786 2022年3月
-
Misumi I, Sato K, Nagano M, Korogi W, Usuku H, Kaikita K, Tsujita K
Journal of echocardiography 20 ( 1 ) 59 - 61 2022年3月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Echocardiography
-
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial. 査読あり
Matsui K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Ogawa H
BMC medicine 20 ( 1 ) 69 2022年2月
-
Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome. 査読あり
Fujisue K, Yamamoto E, Sueta D, Takae M, Nishihara T, Komorita T, Usuku H, Yamanaga K, Ito M, Hoshiyama T, Kanazawa H, Takashio S, Arima Y, Araki S, Soejima H, Kaikita K, Matsushita K, Tsujita K
International journal of cardiology 349 1 - 6 2022年2月
-
Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases-INVITATION Trial. 査読あり
Shirakawa T, Fujisue K, Nakamura S, Yamamoto N, Oshima S, Matsumura T, Tsunoda R, Hirai N, Koide S, Tayama S, Kikuta K, Hirose T, Maruyama H, Fujimoto K, Kajiwara I, Sakamoto T, Nakao K, Sakaino N, Nagayoshi Y, Hokamaki J, Shimomura H, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Ogawa H, Tsujita K
Journal of atherosclerosis and thrombosis 29 ( 2 ) 229 - 241 2022年2月
-
Effect of the ALDH2 Variant on the Prevalence of Atrial Fibrillation in Habitual Drinkers. 査読あり
Yamashita T, Arima Y, Hoshiyama T, Tabata N, Sueta D, Kawahara Y, Ito M, Kanazawa H, Ishii M, Yamanaga K, Hanatani S, Takashio S, Araki S, Suzuki S, Yamamoto E, Kaikita K, Oniki K, Saruwatari J, Matsushita K, Tsujita K
JACC. Asia 2 ( 1 ) 62 - 70 2022年2月
-
Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. 査読あり
Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejima H, Matsushita K, Tsujita K
Nutrition, metabolism, and cardiovascular diseases : NMCD 32 ( 5 ) 1227 - 1235 2022年1月
-
Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS). 査読あり
Ahmed K, Arima Y, Tabata N, Ishii M, Sato R, Yamashita T, Yamanaga K, Takizawa H, Hokimoto S, Sueta D, Araki S, Fujisue K, Takashio S, Fujimoto K, Shimomura H, Tsunoda R, Hirose T, Sato K, Kikuta K, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Tayama S, Sakamoto T, Nakao K, Oshima S, Yamamoto E, Sakamoto K, Kaikita K, Matsushita K, Tsujita K
Heart and vessels 37 ( 6 ) 911 - 918 2022年1月
-
Lotus Root-Like Appearance of a Lipid-Rich Plaque in a Patient With Acute Myocardial Infarction - Findings From Near-Infrared Spectroscopy and Optical Coherence Tomography. 査読あり
Nishihira K, Shibata Y, Kaikita K
Circulation reports 4 ( 1 ) 66 - 67 2022年1月
-
Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. 査読あり
Hirakawa K, Yamamoto E, Takashio S, Hanatani S, Araki S, Suzuki S, Kaikita K, Matsushita K, Ogo T, Tsujita K
Cardiovascular intervention and therapeutics 37 ( 1 ) 60 - 65 2022年1月
-
HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. 査読あり
Egashira K, Sueta D, Komorita T, Yamamoto E, Usuku H, Tokitsu T, Fujisue K, Nishihara T, Oike F, Takae M, Hanatani S, Takashio S, Ito M, Yamanaga K, Araki S, Soejima H, Kaikita K, Matsushita K, Tsujita K
The Korean journal of internal medicine 37 ( 1 ) 96 - 108 2022年1月
-
Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey 査読あり
Shimamura M., Kaikita K., Nakagami H., Kawano T., Ju N., Hayashi H., Nakamaru R., Yoshida S., Sasaki T., Mochizuki H., Tsujita K., Morishita R.
Scientific Reports 11 ( 1 ) 11472 2021年12月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Scientific Reports
In post-stroke patients, a decreased adherence to antiplatelet drugs is a major challenge in the prevention of recurrent stroke. Previously, we reported an antiplatelet vaccine against S100A9 in mice, but the use of Freund’s adjuvant and the difference in amino acid sequences in epitopes between mice and humans were problematic for clinical use. Here, we redesigned the S100A9 vaccine for the common sequence in both humans and monkeys and examined its effects in cynomolgus monkeys with Alum adjuvant. First, we assessed several candidate epitopes and selected 102 to 112 amino acids as the suitable epitope, which could produce antibodies. When this peptide vaccine was intradermally injected into 4 cynomolgus monkeys with Alum, the antibody against human S100A9 was successfully produced. Anti-thrombotic effects were shown in two monkeys in a mixture of vaccinated serum and fresh whole blood from another cynomolgus monkey. Additionally, the anti-thrombotic effects were partially inhibited by the epitope peptide, indicating the feasibility of neutralizing anti-thrombotic effects of produced antibodies. Prolongation of bleeding time was not observed in vaccinated monkeys. Although further studies on increasing the effect of vaccine and safety are necessary, this vaccine will be a promising approach to improve adherence to antiplatelet drugs in clinical settings.
-
Sirt7 Deficiency Attenuates Neointimal Formation Following Vascular Injury by Modulating Vascular Smooth Muscle Cell Proliferation. 査読あり
Kimura Y, Izumiya Y, Araki S, Yamamura S, Hanatani S, Onoue Y, Ishida T, Arima Y, Nakamura T, Yamamoto E, Senokuchi T, Yoshizawa T, Sata M, Kim-Mitsuyama S, Nakagata N, Bober E, Braun T, Kaikita K, Yamagata K, Tsujita K
Circulation journal : official journal of the Japanese Circulation Society 85 ( 12 ) 2232 - 2240 2021年11月
-
Associations of cardiovascular risk factors with survival outcomes in a cancer registration: Findings from the KUMAMON registry. 査読あり
Maki Y, Sueta D, Ishii M, Yamanouchi Y, Fujisue K, Yamanaga K, Nakamura T, Tabata N, Arima Y, Araki S, Yamamoto E, Kaikita K, Chikamoto A, Matsushita K, Matsuoka M, Usuku K, Tsujita K
Medicine 100 ( 47 ) e27921 2021年11月
-
重症再生不良性貧血を合併した不安定狭心症に対し人工心肺非使用冠動脈バイパス術を施行した1例
廣田貴史, 定永達明, 高木淳, 西川幸作, 吉永隆, 岡本健, 海北幸一, 辻田賢一, 福井寿啓.
心臓 53 ( 11 ) 1213 - 1219 2021年11月
掲載種別：研究論文（学術雑誌）
-
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial. 査読あり
Matoba T, Yasuda S, Kaikita K, Akao M, Ako J, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators.
JACC. Cardiovascular interventions 14 ( 21 ) 2330 - 2340 2021年11月
-
Aspirin versus P2Y<inf>12</inf>inhibitors with anticoagulation therapy for atrial fibrillation 査読あり
Fukaya H., Ako J., Yasuda S., Kaikita K., Akao M., Matoba T., Nakamra M., Miyauchi K., Hagiwara N., Kimura K., Hirayama A., Matsui K., Ogawa H.
Heart 107 ( 21 ) 1731 - 1738 2021年11月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Heart
Objective: Patients with coronary artery disease (CAD) and atrial fibrillation (AF) can be treated with multiple antithrombotic therapies including antiplatelet and anticoagulant therapies; however, this has the potential to increase bleeding risk. Here, we aimed to evaluate the efficacy and safety of P2Y12 inhibitors and aspirin in patients also receiving anticoagulant therapy. Methods: We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician's discretion. The primary efficacy and safety end points, consistent with those of the AFIRE trial, were compared between P2Y12 inhibitors and aspirin groups. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularisation or death from any cause. The primary safety end point was major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Results: A total of 1075 patients were included (P2Y12 inhibitor group, n=297; aspirin group, n=778). Approximately 60% of patients were administered proton pump inhibitors (PPIs) and there was no significant difference in PPI use in the groups. There were no significant differences in the primary end points between the groups (efficacy: HR 1.31; 95% CI 0.88 to 1.94; p=0.178; safety: HR 0.79; 95% CI 0.43 to 1.47; p=0.456). Conclusions: There were no significant differences in cardiovascular and bleeding events in patients with AF and stable CAD taking rivaroxaban with P2Y12 inhibitors or aspirin in the chronic phase. Trial registration number: UMIN000016612; NCT02642419.